DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 206426/S-004

SUPPLEMENT APPROVAL

BioCryst Pharmaceuticals, Inc.
Attention: Elliott T. Berger, PhD
Sr. Vice President, Regulatory Affairs
4505 Emperor Blvd. Suite 200
Durham, NC 27703

Dear Dr. Berger:

Please refer to your Supplemental New Drug Application (sNDA) dated March 24, 2017, received March 24, 2017, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for RAPIVAB™ (peramivir injection) for intravenous use, 200 mg/20 ml.

This Prior Approval supplemental new drug application proposes the following changes:

- To expand the patient population of RAPIVAB (peramivir) to include the treatment of acute uncomplicated influenza in patients 2 years and older who have been symptomatic for no more than two days
- To revise the labeling based upon the Pregnancy and Lactation Labeling Rule (PLLR)

APPROVAL and LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER of HIGHLIGHTS SECTION

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT of LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at

http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We note that you have fulfilled the pediatric studies requirement for ages 2 to less than 18 years old for this application.

POSTMARKETING COMMITMENTS SUBJECT to REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitments:

3268-1	Conduct additional sequencing of the hemagglutinin (HA) and neuraminidase (NA) genes from the viral isolates obtained on Day 1 and Day 3 from two subjects (Subjects 005.001 and 020.013, respectively), enrolled in Study BCX1812-305, in order to identify the genetic basis for the >3-fold shifts in susceptibility to peramivir, oseltamivir, and/or zanamivir. Should variants that account for the shift in susceptibility not be detected by bulk RNA sequencing (e.g. Sanger sequencing), other means of identifying minor resistant variants will need to be employed, such as sequencing multiple virus clones isolated in a plaque assay in the

presence of drug or by deep sequencing of the HA and NA genes from the virus isolate and clinical specimens.

The timetable you submitted on August 31, 2017, states that you will conduct this study according to the following schedule:

Final Report Submission: 12/2018

3268-2 Evaluate the impact of hemagglutinin (HA) substitution V496F (V479F based on the H1N1 HA numbering convention described in the label), identified as treatment-emergent in one subject enrolled in Study BCX1812-305 (Subject 009.009), on peramivir susceptibility of H1N1 virus in a relevant cell culture-based assay appropriate for assessing neuraminidase inhibitor susceptibility.

The timetable you submitted on August 31, 2017, states that you will conduct this study according to the following schedule:

Final Report Submission: 12/2018

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call me, Andrew Gentles, PharmD, BCPS AQ-ID, Regulatory Project Manager, at (240) 402-5708.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, MD
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DEBRA B BIRNKRANT
09/20/2017